Breast cancer (BC) remains the main oncological pathology in the female population. Liver metastases in such cases mean an extremely unfavorable prognosis of the course of the disease. The key predictor of clinical outcome of metastatic BC is the molecular biological subtype of the tumor. The main goals of treatment of metastatic BC are to increase life expectancy, alleviate tumor-related symptoms, and maintain or improve patients' quality of life. Transarterial chemoembolization (TACE) enables new ways of liver metastases control. This article presents a case of application of TACE in combination with hormone therapy and selective inhibitors of CDK4/6 in a patient with unresectable liver metastases seeded by hormone-receptor positive (ER⁺/PR^‒) breast carcinoma with an unknown Her2 status (2⁺). The approach allowed achieving regression of the oncological process in the liver to the point of unclear CT visualizations of metastatic foci, and proper disease control in the course of 28 months.